The future of Ischemic Heart Disease prevention will be won through metabolic diagnostics.

Ischemic heart disease (IHD) remains the leading cause of death in the United States, but its age-standardized mortality rate has fallen sharply—down 58.7% from 1990 to 2023.

Despite this progress, the vast majority of IHD deaths (88.7%) are still attributable to modifiable risk factors, underscoring persistent gaps in prevention.

The Global Burden of Disease (GBD) 2023 analysis quantified how risk factor patterns have shifted over three decades:

• High systolic blood pressure, dietary risks, and high LDL cholesterol were the top contributors to IHD mortality in 2023.

• High BMI and high fasting plasma glucose showed the largest increases in attributable mortality since 1990—reflecting worsening obesity and diabetes trends.

• In contrast, smoking and particulate matter pollution saw major declines in attributable mortality, aligning with public health successes in tobacco control and air quality improvements.

Overall, the study highlights that while IHD mortality has dropped substantially, rising metabolic risk factors—especially obesity and dysglycemia—are now driving a growing share of preventable deaths. Strengthening policies and interventions that reduce exposure to these risks is essential to further lowering IHD mortality nationwide.

The takeaway: Cardiovascular prevention is increasingly a metabolic challenge. Diagnostics, risk stratification tools, and guideline-aligned screening will be central to bending the curve further.